INNOVATE Corp. Q1 FY2026 earnings call

• Overall Company Performance

  • InnovateCorp delivered consolidated Q1 2026 revenue of $364.8 million (up 33% YoY) and adjusted EBITDA of $19.7 million (up from $7.2 million YoY). The net loss attributable to shareholders decreased to $17.2 million ($1.29 per diluted share) from $24.8 million ($1.89 per diluted share) YoY. As of March 31 2026, the company held $134.6 million in unrestricted cash and had $699 million in total outstanding debt.
  • Management is working with lenders on strategic alternatives to fix the company's capital structure, and will provide updates as strategy is executed.

• Infrastructure Segment (DBM Global)

  • Gross margin compressed 140 basis points YoY to 14.2%, while adjusted EBITDA margin of 6.4% remained consistent with the prior year quarter.
  • Sales activity remained healthy, with disciplined project pursuit and strong conversion driving meaningful backlog growth. The segment exited the quarter with strong momentum and an improving pipeline, with early success building 2027 project backlog.
  • Key growth drivers are technology-related construction (AI infrastructure, data centers, chip manufacturing, energy systems, advanced manufacturing, digital connectivity), healthcare infrastructure, and projects in New York City, which have pushed backlog near record levels.
  • Management is shifting focus from near-term execution to disciplined, capacity-aligned growth to maintain margins, operational flexibility, and long-term value.

• Life Sciences Segment

  • MetaBeacon completed a notified body quality systems audit with no observations, enabling streamlined regulatory approval across the US, Europe, Japan, Australia, Canada, and Brazil. MetaBeacon secured CE marking for the TGFR monitor and reusable sensor under EU MDR, and is targeting additional Asia-Pacific market approvals in 2026 with its partner.
  • Multiple clinical programs advanced: the Surgical Vigilation study has enrolled initial patients, the and geography study received FDA IDE and hospital board approval with recruitment underway, the TGFR wireless sensor study received FDA IDE approval with planned 2026 enrollment, and the renal functional reserve study also secured FDA IDE approval.
  • R2, the segment's commercial product, generated $1.6 million in Q1 2026 revenue with total demand of $2.2 million. International system sales grew 58.6% YoY, and R2 added a new South Korean distributor representing a $2 million revenue opportunity. R2 currently holds a 160-system backlog worth ~$2 million in revenue, with strong momentum into Q2. R2 is seeking external capital to continue its growth in 2026.

• Spectrum Segment

  • The segment continues to face near-term headwinds from soft advertising demand and network cancellations, but has advanced multiple strategic initiatives.
  • The 2026 NAB conference generated multiple new strategic and commercial opportunities that the company is actively following up on.
  • Favorable FCC rulings created opportunities to expand and optimize the US spectrum footprint with low marginal cost over 6-12 months. The company filed for over 60 new low-power TV licenses in the March filing window, and relocated 25 Class A licenses from smaller to larger markets to improve spectrum protection and positioning for future auctions. Construction permits are expected in the coming months, with up to three years to complete build-outs.
  • A collaborative trial with a mobile wireless carrier was completed successfully, and discussions for new market launches in H2 2026 are ongoing. The company's FCC petition for 5G broadcast conversion of low-power television has gained industry support, though no formal FCC action has been taken yet.

1. Infrastructure: Q1 2026 revenue was $357.9 million, a 35.1% increase from $264.9 million in Q1 2025. Adjusted EBITDA increased to $23 million from $16.7 million year-over-year. This segment contributed 98.1% of InnovateCorp's total consolidated Q1 2026 revenue. As of March 31 2026, DBM Global had $76.6 million in principal debt, down $11.1 million from end-2025, and maintained an adjusted backlog of $1.8 billion, flat from end-2025.
2. Life Sciences: Q1 2026 revenue decreased 48.4% to $1.6 million from $3.1 million in Q1 2025. The segment contributed 0.44% of total Q1 2026 revenue. Adjusted EBITDA losses narrowed year-over-year, driven by fewer equity method losses from MetaBeacon and lower SG&A expenses.
3. Spectrum: Q1 2026 revenue was $5.3 million, a $0.9 million decrease from Q1 2025. Adjusted EBITDA decreased to $0.7 million from $1.4 million year-over-year. This segment contributed 1.45% of total Q1 2026 revenue. The revenue and EBITDA decline was driven by network cancellations in individual markets.
4. Non-operating Corporate: Adjusted EBITDA losses were $2 million in Q1 2026, slightly down from $2.2 million in Q1 2025.

Management did not issue formal revised full-year or quarterly financial guidance during this Q1 2026 earnings call. Management confirmed confidence in the durability of the Infrastructure segment's revenue base, and noted potential incremental upside as project timing and scope firm up, with strong visibility for 2026 and early momentum building 2027 backlog. Management expects Spectrum's performance to improve as market conditions normalize, following current strategic investments and regulatory tailwinds.

Forward-looking statements provided during the call are subject to known and unknown risks, assumptions, and uncertainties that could cause actual results to differ materially from projected outcomes, with detailed risk factors disclosed in the company's SEC filings (10-K, earnings release, and slide presentation). The company has an ongoing need to address its capital structure, and is currently working with lenders on strategic alternatives. The Spectrum segment faces ongoing near-term headwinds from soft advertising demand and recent network cancellations. No formal action has yet been taken by the FCC on the company's 5G broadcast conversion petition, so that strategic opportunity remains uncertain. R2 requires external capital to continue its growth and development through 2026. Project timing and scope for Infrastructure segment projects have not yet fully firmed up, creating uncertainty around near-term and medium-term revenue upside.

No investor or analyst questions were received during the opened Q&A session, so no exchanges occurred in this portion of the call. The Q&A session was closed promptly after no questions entered the queue, and the call moved directly to closing remarks from interim CEO Paul Voigt.